DUBLIN--(BUSINESS WIRE)--Dec 28, 2020--
The "Hepatitis C Virus (HCV) - Epidemiology Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.
This report delivers an in-depth understanding of the disease, historical and forecasted HCV epidemiology in the 7MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
HCV is diagnosed based on the patient's medical history, a physical exam, and blood tests. If a viral infection is confirmed, doctors may suggest additional tests to check the condition of the liver.
Initial testing for the diagnosis of hepatitis C infection uses serologic assays that detect human antibodies generated as a response to HCV infection. Blood tests for HCV include screening tests for antibodies to the HCV virus, HCV RNA test, Genotype test, etc.
In Chronic HCV, doctors may recommend additional tests to find out how much liver damage the patient has, or to rule out other causes of liver disease. These tests may include blood tests, Imaging Tests (Transient elastography, Ultrasound, MRI, and CT Scan), and Liver function Tests (ALT, AST, ALP, and total bilirubin). If the liver is damaged due to inflammation, enzymes pass out of the liver into the bloodstream, making ALT and AST levels higher than normal. The doctor may also recommend a liver biopsy if blood tests or imaging studies suggest the patient might have a liver problem. A biopsy can determine the extent of scarring, or fibrosis, in a liver affected by viral hepatitis.
Key Questions Answered
- What will be the growth opportunities in the 7MM concerning the patient population of HCV?
- What are the key findings of the HCV epidemiology across the 7MM and which country will have the highest number of patients during the study period (2017-2030)?
- What would be the total number of patients of HCV across the 7MM during the study period (2017-2030)?
- Among the EU5 countries, which country will have the highest number of patients during the study period (2017-2030)?
- At what CAGR the patient population is expected to grow in the 7MM during the study period (2017-2030)?
- What are the various recent and upcoming events which are expected to improve the diagnosis of HCV?
Reasons to Buy
- Develop business strategies by understanding the trends shaping and driving the global HCV market
- Quantify patient populations in the global HCV market to improve product design, pricing, and launch plans
- Organize sales and marketing efforts by identifying the gender that presents the best opportunities for HCV therapeutics in each of the markets covered
- Understand the magnitude of HCV population by its severity
- The HCV epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists
- The HCV Epidemiology Model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over an 11-year forecast period using reputable sources
Key Topics Covered:
1. Key Insights
2. Executive Summary of the Hepatitis C Virus (HCV)
3. SWOT Analysis of Hepatitis C Virus (HCV)
4. Epidemiology Methodology
5. Hepatitis C Virus (HCV): Disease Background and Overview
5.1.1. Signs and Symptoms of HCV
5.1.2. Risk Factors and Causes of HCV
5.1.3. Pathophysiology of HCV
5.1.4. Complications of HCV Infection
6. Diagnosis of Hepatitis C Infection
6.1. Screening for HCV infection
6.2. HCV RNA Testing
6.3. HCV Genotype Testing
6.4. HCV Resistance Testing (RAV testing)
6.5. Tests to Diagnose HCV
6.5.1. Medical History and Physical exam
6.5.2. Imaging Tests
6.5.3. Liver Biopsy
6.6. The differential diagnosis for Hepatitis C
7. Prevention of HCV
8. Diagnostic Guidelines of HCV
8.1. Centers for Disease Control and Prevention (CDC) Recommendations for Hepatitis C screening among Adults in the United States
8.2. US Preventive Services Task Force (USPSTF) Recommendations for the screening of HCV infection in Adolescents and Adults
8.3. American Association for the Study of Liver Diseases (AASLD) Diagnostic Guidelines
8.4. World Health Organization (WHO) Diagnostic Guidelines
8.5. EASL recommendations on treatment of hepatitis C 2020
9. Epidemiology and Patient Population
9.1. Epidemiology Key Findings
9.2. Assumptions and Rationale: 7MM
10. Epidemiology Scenario: 7MM
10.1. Total Prevalent Cases of HCV in the 7MM
10.2. Total Diagnosed cases of HCV in the 7MM
10.3. Gender-specific cases of HCV in the 7MM
10.4. Age-specific Diagnosed Cases of HCV in the 7MM
10.5. Genotype-specific Diagnosed Cases of HCV in the 7MM
10.6. Diagnosed Cases of HCV by Impact on Liver in the 7MM
10.7. Treated cases of HCV in the 7MM
11. The United States Epidemiology
12. EU-5 Epidemiology
12.5. The United Kingdom
13. Japan Epidemiology
15. Publisher Capabilities
17. About the Publisher
For more information about this report visit https://www.researchandmarkets.com/r/485v0e
View source version on businesswire.com:https://www.businesswire.com/news/home/20201228005152/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
KEYWORD: UNITED STATES UNITED KINGDOM GERMANY JAPAN FRANCE ITALY SPAIN NORTH AMERICA ASIA PACIFIC EUROPE
INDUSTRY KEYWORD: GENERAL HEALTH HEALTH MEDICAL SUPPLIES MEDICAL DEVICES
SOURCE: Research and Markets
Copyright Business Wire 2020.
PUB: 12/28/2020 07:20 AM/DISC: 12/28/2020 07:20 AM